Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 5th, 2026

LECO_Weekly-Healthcare-News_10-05-2026Download

Healthcare Weekly News and Deals – Oct 5th, 2026

  1. Smart ring maker Oura has postponed its Nasdaq IPO, which would have raised up to $2.2 billion through the sale of 50 million shares, citing uncertainty in the listing market just eight days after formally launching the process. Oura delayed its planned Nasdaq listing despite what it described as strong demand and a strengthening of the business since the IPO process began. The company launched its plans on September 21 and had intended to raise up to $2.2 billion by selling 50 million shares. CEO Tom Hale said Oura aims to deliver an extraordinary IPO for employees and investors and has “the luxury of choosing our moment.” Oura says it is profitable, with revenue expected to grow 90% year over year in fiscal 2026. It follows Holtec Nuclear’s withdrawal earlier in the month. (Link)
  2. U.S. healthcare technology investor Thoreau has committed $500 million to launch Ortet, a frontier AI lab for health building models that connect patient biology, treatment and healthcare administration. Ortet launched on September 29, 2026 with a $500 million commitment from Thoreau, bringing together former drug industry and technology company researchers. The company plans to use the backing to build computing and data infrastructure, train and deploy health-focused models, and recruit researchers and engineers. Ortet has already secured an initial cluster of graphics processing units, the specialized chips used to train and run AI systems. Rather than targeting a single clinical task, the lab is building models intended to link patient biology, treatment and healthcare administration, making it one of the largest single capital commitments to a healthcare AI company at formation. (Link)
  3. Grindr (NYSE:GRND) has agreed to acquire PurposeMed, the parent company of HIV-prevention telehealth provider Freddie, in a $250 million cash-and-stock deal with up to $70 million of additional performance consideration. Grindr will pay $190 million in cash and $60 million in common stock for PurposeMed, with up to $70 million in further cash tied to Freddie’s 2027 performance and payable in 2028. The transaction is expected to close in the fourth quarter and is Grindr’s first major acquisition since its 2009 founding. CEO George Arison said the healthcare line could become as profitable and as large as the core business, and that building it internally would have taken two to three years. Grindr expects the combined U.S. telehealth and pharmacy business to generate more than $400 in monthly revenue per active patient, implying roughly $240 million of annual revenue at 50,000 patients. (Link)
  4. Inogen (NASD: INGN) has agreed to divest its U.S. oxygen rental business to national home respiratory provider Rotech Healthcare for estimated cash consideration of up to $25 million. Inogen (INGN) signed a definitive agreement to sell specified U.S. oxygen rental assets to Rotech Healthcare for total estimated cash consideration of up to $25 million, with closing expected in the fourth quarter of 2026. The rental business generated $24.3 million of revenue in the first half of 2026, a 9.8% year-over-year decline, and will be presented as discontinued operations beginning in Q3. Inogen expects the transactions to increase both its revenue growth rate and adjusted operating income. Subject to closing, the board approved a $15 million increase to the share repurchase authorization, taking it to $45 million through June 2028. (Link)
  5. Interpace Biosciences (IDXG) has filed terms for a $20 million offering of 3.1 million shares at an assumed $6.47 per share to support a proposed uplisting from OTC to Nasdaq. Interpace Biosciences (IDXG), the Parsippany, New Jersey molecular diagnostics company behind the ThyGeNEXT and ThyraMIR v2 thyroid tests, filed terms on September 25, 2026 for a $20 million deal covering 3.1 million shares at an assumed $6.47; the offering remains unpriced. The raise follows an August reverse stock split announced to support the proposed Nasdaq uplisting. Thyroid test volume rose from 25,200 in 2022 to 36,200 in 2025 and pro forma revenue grew from $20.3 million to $34.8 million, a 19.7% CAGR, after the company stopped accepting PancraGEN specimens in May 2025 following a loss of CMS reimbursement. (Link)
  6. KALA Bio (NASD: KALA) has signed a non-binding letter of intent to acquire 100% of a privately held U.S. telehealth management services organization for approximately $15 million in cash and KALA stock. KALA Bio (KALA) signed the LOI on September 24, 2026 for an MSO supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform operating in all 50 states across GLP-1 weight management, hormone health, longevity and sexual wellness. The target generated roughly $12.7 million of unaudited revenue for the trailing twelve months ended August 2026, over $48 million of sales since its 2023 founding, has served more than 90,000 clients and is described as cash-flow positive. The cash portion would come from existing balance sheet resources, with closing targeted for late 2026 or early 2027. (Link)
  7. SpyGlass Pharma (NASD: SGP) has acquired Advanced Vision Science from Santen for about $13 million in cash. Advanced Vision Science has made intraocular lenses since 1975 and supplies Santen’s Eternity lens in Japan. It also licenses glistening-free hydrophobic acrylic material to Bausch + Lomb for the enVista line. Those supply and license arrangements stay in place. SpyGlass, which is developing a drug-pad lens implanted during cataract surgery for glaucoma, is buying the plant to secure commercial lens supply. (Link)
  8. Shionogi has agreed to acquire Austin-based IntraBio for $2.0 billion, adding the rare-disease therapy AQNEURSA. Shionogi is buying all outstanding shares of IntraBio, an Austin company founded in 2015, for $2.0 billion in upfront cash. IntraBio sells AQNEURSA, approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C and, as of September 18, for ataxia in ataxia-telangiectasia in the United States. The company becomes a subsidiary of Shionogi’s New Jersey unit. Closing is scheduled for November or December, subject to antitrust review. Shionogi bought the RADICAVA ALS franchise in April. (Link)
  9. AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics (NASD: SMMT), taking about a 12 percent stake. AstraZeneca is buying convertible preferred equal to about 12 percent of Summit’s common stock, or 10.6 percent fully diluted. The stake sits alongside a clinical collaboration testing AstraZeneca’s Claudin-18.2 antibody-drug conjugate, sonesitatug vedotin, with Summit’s PD-1/VEGF bispecific ivonescimab in gastrointestinal cancers. Each company keeps rights to its own drug. The investment was announced September 29 and was expected to close within about a week. (Link)
  10. GE HealthCare (NASD: GEHC) has agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE is a U.S. contract manufacturer for PET radiopharmaceuticals, with 15 sites, 21 cyclotrons and a theranostics development site, plus U.S. rights to FAPI-74, a Phase III PET tracer aimed at pan-cancer imaging. The business will sit in GE HealthCare’s pharmaceutical diagnostics segment and gives the buyer a last-mile network for short-lived tracers. Closing is aimed at the first half of 2027, subject to regulatory approval. (Link)
  11. Lantern Pharma (NASD: LTRN) has agreed to sell 3,669,725 shares at $1.09 in a registered direct offering raising approximately $4 million, with up to $4 million more available from concurrent private placement warrants. Lantern Pharma (LTRN), a clinical-stage AI-native precision oncology company, entered a definitive agreement for a registered direct offering of 3,669,725 shares, or pre-funded warrants in lieu, priced at $1.09 each. Aggregate gross proceeds are expected to be about $4 million. In a concurrent private placement, investors receive unregistered warrants over an equal number of shares at a $1.09 exercise price, exercisable only after stockholder approval and expiring five years later; full cash exercise would add roughly $4 million. Closing was expected on or about September 30, 2026, with proceeds earmarked for working capital and general corporate purposes. (Link)
  12. Leica Biosystems, a Danaher (NYSE: DHR) company, has completed its acquisition of pre-analytical consumables maker StatLab Medical Products from private equity owners Linden Capital Partners and Audax Private Equity. Danaher (DHR) subsidiary Leica Biosystems completed its purchase of privately held StatLab Medical Products on September 28, 2026, acquiring the business from Linden Capital Partners and Audax Private Equity. Terms were not disclosed. The deal extends Leica’s end-to-end anatomic pathology portfolio across specimen collection and preparation, advanced staining, digital imaging and AI-enabled diagnosis. Management positioned the combination as a response to laboratories facing rising case volumes, increasing complexity and staffing pressure, and as support for Leica’s biopharma partnerships within Danaher’s connected diagnostics ecosystem. (Link)
  13. Goldman Sachs (NYSE: GS) and Charlesbank Capital Partners-backed MyEyeDr. has agreed to acquire the 300-plus office optometry division of Partners Group (SWX: PGHN)-owned EyeCare Partners for an undisclosed sum. MyEyeDr., backed by Goldman Sachs (GS) and Charlesbank Capital Partners, is buying EyeCare Partners’ optometry division, which spans more than 300 offices under the Clarkson Eyecare, EyeCare Associates, EyeCare Center, Nationwide Vision and The Eye Doctors brands. Partners Group (PGHN) acquired EyeCare Partners in a $2.2 billion deal in late 2019, while Goldman Sachs bought MyEyeDr. for $2.7 billion the same year; MyEyeDr. already runs roughly 1,000 locations across about 30 states. EyeCare Partners will apply proceeds to reduce debt and strengthen liquidity while focusing on ophthalmology and ambulatory surgical centers. Closing is expected in Q4 2026. (Link 1) (Link 2)
  14. APM Group has agreed to acquire occupational health provider Medcor, combining it with previously acquired WorkCare and its Assure employee assistance business into a 2,000-employee North American platform. APM Group announced on September 28 that it entered an agreement to acquire Medcor, subject to Federal Trade Commission approval, with financial terms and completion date undisclosed. The deal follows APM’s April acquisition of WorkCare. Combined with Assure, the three businesses would employ more than 2,000 people across 450 sites, with services in every U.S. state and territory and every Canadian province. The combined portfolio spans injury prevention, onsite medical services, occupational health screenings, injury triage, telehealth, case management, return-to-work support and mental health services. Medcor, founded in 1984, adds mobile occupational health and 24/7 telehealth. (Link)
  15. Flexpoint Ford has sold behavioral health pharmacy platform ArtesRx — a business it co-founded in 2023 with Dom Meffe — to healthcare specialist Linden Capital Partners. Flexpoint Ford announced the sale of ArtesRx to Linden Capital Partners for undisclosed terms, a sponsor-to-sponsor exit of a platform Flexpoint built from scratch just three years ago. ArtesRx, established in 2023 by Flexpoint and Dom Meffe, is a behavioral health pharmacy platform serving individuals who depend on complex medication regimens. Chicago-based Flexpoint, founded in 2005, writes $50 million to $500 million per transaction across minority and majority structures in both private and public companies. Linden, also Chicago-based and founded in 2004, invests exclusively in healthcare across services, products and distribution and prefers larger cheques. (Link)
  16. Charlesbank Capital Partners and Warburg Pincus-backed MB2 Dental has partnered with Honolulu-based Hawaii Pacific Dental Group in its 14th acquisition of 2026. MB2 Dental, the Dallas dental support organization backed by middle-market private equity firm Charlesbank Capital Partners and growth equity investor Warburg Pincus, formed a strategic partnership with Hawaii Pacific Dental Group. The Honolulu practice, led by Dr. Rohinton J. Patel, provides cosmetic, restorative, preventative and family dentistry. MB2 supports a nationwide network of more than 1,900 affiliated physicians and practice partners across general dentistry, orthodontics, cosmetic care and oral surgery. The transaction expands MB2’s footprint across Hawaii and the broader Pacific region and marks its 14th acquisition of 2026. Financial terms of the private transaction were not disclosed. Link (Link)
  17. Standard Dental Labs (OTCQB: TUTH) has acquired substantially all operating assets of Dr. Tooth, LLC — also known as Sheen Dental Laboratory and Hansen Incarnati — in a cash-and-stock asset purchase with earnout conditions. Standard Dental Labs (TUTH) closed the acquisition effective October 2, 2026, structured as an asset purchase combining cash and SDL common stock with performance conditions tied to retained customer revenue. Management estimates the acquired business adds just over $800,000 in annualized revenue, taking SDL’s estimated annualized base above $1.6 million and nearly doubling the prior estimate. SDL plans to move production to its Sarasota facility, reshoring work currently outsourced to China to lift utilization and facility profitability. Management believes the business can be rebuilt to more than $1.1 million in annualized revenue. (Link)
  18. Banner Capital, with healthcare private equity firm Seventeen Capital as strategic co-investor, has agreed to acquire Seaway Plastics Engineering, MME Group and Wright Engineered Plastics, forming medical device manufacturing platform Seaway Group under Executive Chairman Ron Labrum. Salt Lake City-based Banner Capital formed Seaway Group and entered a definitive agreement to acquire the three medical device contract manufacturers, with closing expected in the fourth quarter of 2026. Seventeen Capital, a healthcare private equity firm led by medical device executive Ron Labrum, is a strategic co-investor, and Labrum becomes Executive Chairman at close. Seaway Group is the third platform in Banner Capital Fund II, after Western Pavement Services and Roof Restoration Group. Banner targets founder-led Western U.S. businesses with $4 million to $15 million of EBITDA and managed $611 million as of June 30, 2026. (Link)
  19. Wandercraft has acquired Ekso Bionics from a subsidiary of ChronoScale Holdings (NASD: CHRN), uniting two medical exoskeleton pioneers into a global robotic mobility platform. Wandercraft acquired Ekso Bionics from a ChronoScale Holdings (CHRN) subsidiary in a transaction unanimously approved by both boards and signed and closed simultaneously; financial terms were not disclosed. The combination pairs Wandercraft’s advanced robotics, physical AI and EMEA leadership with Ekso’s U.S. presence, clinical evidence base and commercial reach. Atalante X and EksoNR support patients at more than 700 rehabilitation centers worldwide, with FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury, while Eve and Indego Personal address at-home mobility. Wandercraft will continue supporting all four products. (Link)
  20. The University of Kansas Health System has agreed to take full ownership of the St. Francis campus in Topeka from Ardent Health (NYSE: ARDT). The two have run St. Francis and affiliated Topeka sites as a joint venture since 2017, after the campus had been facing closure. Ardent has handled day-to-day operations. KU Health System has provided clinical and financial support. Ardent will stay involved for a period after closing. The transfer is expected by the end of 2026, subject to approvals. (Link)
  21. Biospring Partners has led a growth investment in CDMO Serán Bioscience alongside existing investors Vivo Capital and Bain Capital Life Sciences to fund a new commercial spray-drying facility in Bend, Oregon. Biospring Partners led the growth investment with continued participation from Vivo Capital, Bain Capital Life Sciences and Serán’s executive leadership. Proceeds support a greenfield commercial manufacturing facility on track for completion in Q3 2027, creating an integrated 200,000-plus square foot campus with OEB4 manufacturing, spray drying, nano-milling and finished-dose capabilities. Biospring, founded in 2020, is a healthcare growth buyout firm with more than $500 million under management focused on pharma services; Vivo manages roughly $5.8 billion. Serán employs over 200 people and plans up to 150 additional hires. (Link)
  22. Renovus Capital Partners portfolio company TJP has acquired life sciences market research firm Evolution Consulting & Research, completing an end-to-end research, strategy, creative, pull-through and analytics platform for pharma clients. TJP, a Conshohocken, Pennsylvania value and patient access agency owned by Renovus Capital Partners, acquired Evolution Consulting & Research. The add-on follows TJP’s earlier purchase of FX2 Virtual and gives clients continuity from upfront market research through strategy, creative, virtual field execution and analytics. CEO Rino Mariconda, also an operating partner at Renovus, said the deal fulfills the firm’s vision of a unified platform. Renovus, founded in 2010, invests in knowledge and talent industries including healthcare and life sciences services, and builds platforms through operational improvement and add-on acquisitions. Terms were undisclosed. (Link)
  23. Resonant Clinical Solutions has acquired Hamburg-based labfish rental solutions GmbH and its U.S. and U.K. affiliates, expanding its Equipment & Ancillaries business across Europe. Resonant Clinical Solutions, a Leesburg, Virginia clinical supply chain and sample lifecycle partner, acquired Labfish together with its U.S. and U.K. affiliates for undisclosed terms. Labfish rents scales, freezers, refrigerators, infusion pumps and monitors, supplies kitting and ancillaries, and operates one of the largest in-house calibration facilities serving clinical trials in Europe. It also provides Importer and Exporter of Record services and direct-to-patient logistics, working with partner depots in Argentina, Israel, Turkey and China to supply sites in more than 70 countries. Resonant has over 850 employees and has supported more than 2,500 clinical trials. (Link)
  24. Sheridan Capital Partners has acquired Durham, North Carolina-based single-use bioprocessing components supplier Carolina Components Group, its fourth platform acquisition of 2026. Chicago healthcare private equity firm Sheridan Capital Partners acquired Carolina Components Group, a 2020-founded supplier of ultra-pure components, custom-engineered single-use assemblies and process solutions serving more than 250 biopharmaceutical and contract manufacturing customers. CCG operates over 100,000 square feet of ISO Class 7 and Class 8 cleanroom and manufacturing space, scale Sheridan says regional competitors lack. Sheridan cited CCG’s supplier-agnostic model and its status as a founder-owned business at a growth inflection point. The deal is Sheridan’s fourth of 2026 after ICANotes, Tres Health and PtEverywhere. (Link)
  25. Chicago Pacific Founders has exited veterinary AI company CoVetAI following its acquisition by IDEXX Laboratories (NASD: IDXX), the first realization from CPF’s Pet Fund – Off Leash Capital. IDEXX Laboratories (IDXX) acquired CoVetAI, developer of an AI-powered clinical scribe and workflow platform for veterinary medicine, handing Chicago Pacific Founders the first realization from its specialist animal health fund. Financial terms were not disclosed. CPF was CoVet’s sole institutional investor and backed the company from an early stage; Pet Fund partner Gina Del Vecchio described IDEXX as the ideal owner to scale the product globally. The fund closed on September 16, 2026, holds six portfolio investments, and targets a companion animal market currently worth $288.4 billion and projected to reach $560.7 billion by 2034. (Link)
  26. Brady (NYSE: BRC) has sold its French first-aid business Securimed to Safe Life for about $59 million. Securimed, based in Cappelle-la-Grande, sells customized first-aid kits, protective equipment and emergency-response products, mostly to corporate health and safety departments in France. Brady bought the business in 2010. The price is about €53 million. Brady is an identification and safety-products company based in Milwaukee and is treating the unit as outside that core. (Link)

Venture Deals and Other

  1. Anthropic, PBC has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, with share count and price not yet set. Anthropic, PBC confidentially submitted a draft Form S-1 to the SEC for a proposed initial public offering of its common stock. The submission gives the AI developer the option to go public once the SEC completes its review, with any offering dependent on market conditions and other factors. The number of shares to be offered and the price have not yet been set. The announcement was published under Rule 135 of the Securities Act of 1933 and is not an offer to sell or a solicitation of an offer to buy securities. No valuation, timetable, exchange or selling shareholders were disclosed. (Link 1) (Link 2)
  2. Lux Capital and Natural Capital have co-led a $251 million Series D in El Segundo-based in-orbit pharmaceutical processing company Varda Space Industries, joined by Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital, at a $1.6 billion valuation. Lux Capital and Natural Capital led Varda Space Industries’ $251 million Series D, with Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital participating. The round values the microgravity-enabled life sciences company at $1.6 billion and lifts total capital raised to $598 million. Varda has completed six reentry missions since 2023, with more than a dozen launches and reentries planned through 2028. Proceeds will increase flight cadence and deepen pharmaceutical partnerships toward the first medicine manufactured in space. (Link)
  3. B Capital has led a $33 million Series B in Austin-based microbiome testing company Tiny Health, joined by Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital led Tiny Health’s oversubscribed $33 million Series B, bringing total funding to $46 million. Existing backers Spero Ventures, The Venture City and Overwater Ventures participated alongside new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital manages more than $12 billion and takes a board seat through Senior Principal Nick Whitehead. Proceeds fund clinical research, practitioner education, the Powered by Tiny B2B platform and TinyAI, trained on nearly 200,000 microbiome profiles. Tiny Health also committed $5 million to a Microbiome Research Program. (Link)
  4. Canvas Ventures has led an oversubscribed $10 million Series A in San Francisco-based healthcare AI company Parakeet Health, with Blank Space Ventures, StoryHouse Ventures and HMC INQ participating. Canvas Ventures led Parakeet Health’s oversubscribed $10 million Series A, taking total funding to $13 million. The raise follows 10x annual recurring revenue growth over the past year. Parakeet’s platform manages inbound calls, proactive outreach, fax processing and web scheduling, and now serves six of the ten largest U.S. dermatology groups, supporting more than 2,800 providers across 1,100-plus locations. Canvas co-founder Rebecca Lynn cited the team’s ability to win major healthcare customers and deliver measurable ROI. Parakeet charges on a performance basis tied to verified results. Link (Link)
  5. Biotia has raised an oversubscribed $9 million financing from Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, alongside VillageMD co-founders Tim Barry and Clive Fields. New York clinical metagenomics company Biotia closed an oversubscribed $9 million round that exceeds its previously announced Series A. Investors include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, plus VillageMD co-founders Tim Barry and Clive Fields. DigitalDx Ventures CEO Michele Colucci becomes board chair and Barry joins the board. Capital will scale Biotia’s New York laboratory, launch further women’s health diagnostics and expand into orthopedics. Its BIOTIA-ID urine test reports 97% sensitivity and 99% specificity. (Link)
  6. Cobalt Capital has led an undisclosed Series A in Los Angeles-based predictive movement health company p°Motion, joined by WME Group, Nimble Ventures, Canaan Ventures and Soul Ventures. Cobalt Capital led the Series A financing, building on support from a broader investor group including WME Group, Nimble Ventures, Canaan Ventures, Soul Ventures and strategic investors connected to professional sports, technology and institutional capital. Neither round size nor valuation was disclosed. Founded in 2019, p°Motion applies machine learning to an assessment methodology built on more than 40 years of movement research, and says it can identify certain injury risks up to 18 months before they occur — a company-reported claim without published validation data. Proceeds fund AI and engineering hiring plus commercial expansion into healthcare. (Link)
  7. Advent has led, and Temasek co-led, a $555 million Series G in Medicare Advantage insurer Devoted Health as part of a $1.18 billion financing. Devoted Health closed $555 million of Series G primary funding within a $1.18 billion primary and secondary financing. Advent led with Temasek as co-lead, joined by The Space Between — both independently and alongside Centricus — plus GIC, Franklin Templeton, Generation, VZVC, Emerson Collective, Premji Invest and Andreessen Horowitz. The same investors committed $622 million for a shareholder tender offer expected to close later in the fourth quarter. Membership has grown from 212,000 in December 2025 to 538,000 by September 2026, and Devoted is entering 342 new counties and five new states. (Link)

CLICK HERE to sign up
for all news and updates